Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 3/17/20 (What's New)

Summary

  • In recent clinical trials of antiretroviral-naive patients, the proportion of patients achieving undetectable HIV-1 RNA was approximately 90%
  • For some patients there are often important, nonvirologic reasons to modify their antiretroviral regimen, such as drug intolerance or the need to simplify the regimen

Action required

Keywords: Switch Strategies

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.